Pharmacokinetic Study of AJM300 in Subjects with Hepatic Impairment: Clinical Pharmacology Study Comparing Safety, Tolerability, and Pharmacokinetics of AJM300 between Subjects with Hepatic Impairment and Normal Subjects
Latest Information Update: 27 Sep 2022
At a glance
- Drugs Carotegrast (Primary)
- Indications Liver cirrhosis; Liver disorders
- Focus Adverse reactions
- Sponsors EA Pharma
- 19 Dec 2021 Planned initiation date changed from 30 Jun 2019 to NULL.
- 19 Dec 2021 New trial record